Inventiva (IVA) has released an update.
Inventiva, a clinical-stage biopharmaceutical company, has reported its first-quarter financials for 2024, showing cash and deposits totaling €30.2 million, a significant increase in R&D expenses due to the NATiV3 Phase III clinical trial for MASH/NASH treatment, and an extended cash runway anticipated until Q3 2024. They have resumed patient screening across 280 sites globally for the NATiV3 trial, with strategic financing plans under review to address future capital needs, given existing material uncertainties.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
